References
- Holland TL, Baddour LM, Bayer AS, et al. Infective endocarditis HHS public access. Nat Rev Dis Primers. 2017;2:1–49.
- Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075–3128.
- Fernández-Hidalgo N, Almirante B. Estado actual de la endocarditis infecciosa: nuevas poblaciones de riesgo, nuevos retos diagnósticos y terapéuticos. Enferm Infecc Microbiol Clin. 2018;36(2):69–71.
- Utili R, Durante-Mangoni E, Tripodi MF. Infection of intravascular prostheses: how to treat other than surgery. Int J Antimicrob Agents. 2007;30(1):42–50.
- Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415–424.
- Camazon NV, Mateu L, Cediel G, et al. Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis. Cardiol J. 2021;28(4):566–578.
- Baddour LM. Long-term suppressive antimicrobial therapy for intravascular device-related infections. Am J Med Sci. 2001;322(4):209–212.
- Tan EM, DeSimone DC, Sohail MR, et al. Outcomes in patients with cardiovascular implantable electronic device infection managed With chronic antibiotic suppression. Clin Infect Dis. 2017;64(11):1516–1521.
- Puerta-Alcalde P, Cuervo G, Simonetti AF, et al. PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis. Infect Dis (Lond). 2017;49(9):698–701.
- Stamboulian D, Bonvehi P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to Penicillin-Susceptible streptococci. Rev Infect Dis. 1991;13(2):13.
- de Velde F, de Winter BCM, Koch BCP, et al. Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. J Antimicrob Chemother. 2016;71(10):2909–2917.
- Stratton CW. Serum bactericidal test. Clin Microbiol Rev. 1988;1:19–26.
- Zaghi I, Gaibani P, Campoli C, et al. Serum bactericidal titres for monitoring antimicrobial therapy: current status and potential role in the management of multidrug-resistant gram-negative infections. Clin Microbiol Infect. 2020;26(10):1338–1344.
- Macheda G, el Helali N, Péan de Ponfilly G, et al. Impact of therapeutic drug monitoring of antibiotics in the management of infective endocarditis. Eur J Clin Microbiol Infect Dis. 2022;41(9):1183–1190.
- Gatti M, Tedeschi S, Trapani F, et al. A proof of concept of the usefulness of a TDM-Guided strategy for optimizing pharmacokinetic/pharmacodynamic target of continuous infusion Ampicillin-Based regimens in a case series of patients with enterococcal bloodstream infections and/or endocarditis. Antibiotics. 2022;11(8):1037.
- Jimenez-Toro I, Rodriguez CA, Zuluaga AF, et al. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: application to ampicillin plus ceftriaxone. PLoS One. 2020;15(12):e0243365.